Diagnosing amyloidosis can be challenging due to its clinical heterogeneity, need for multiple specialists to make a diagnosis, and lack of a single diagnostic test for the disease. Patients are often diagnosed late, in advanced stage, and after exhibiting multiple symptoms and signs for a long period. It is important to develop a clinical suspicion of amyloidosis, particularly in those with multisystemic symptoms and high-risk patient populations such as those with precursor hematologic conditions. A systematic approach to the workup of suspected amyloidosis is key, including a comprehensive clinical assessment, laboratory tests to assess organ involvement, advanced imaging studies, screening for plasma cell disorder, and tissue biopsy when necessary. After making a diagnosis of amyloidosis, accurate typing of amyloid deposits, differentiating between localized and systemic amyloidosis, and appropriately staging the disease is important. Early diagnosis is crucial for improving patient outcomes and quality of life in light chain amyloidosis.

1.
Lousada
I
,
Comenzo
RL
,
Landau
H
,
Guthrie
S
,
Merlini
G.
Light chain amyloidosis: patient experience survey from the amyloidosis research consortium
.
Adv Ther
.
2015
;
32
(
10
):
920
-
928
.
doi:10.1007/s12325-015-0250-0
.
2.
D'Souza
A
,
Myers
J
,
Cusatis
R
, et al.
Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study
.
Qual Life Res
.
2022
;
31
(
4
):
1083
-
1092
.
doi:10.1007/s11136-021-02943-w
.
3.
Buxbaum
JN
,
Dispenzieri
A
,
Eisenberg
DS
, et al.
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee
.
Amyloid
.
2022
;
29
(
4
):
213
-
219
.
doi:10.1080/13506129.2022.2147636
.
4.
Dorbala
S
,
Ando
Y
,
Bokhari
S
, et al.
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization
.
Circ Cardiovasc Imaging
.
2021
;
14
(
7
):
e000030
.
doi:10.1161/HCI.0000000000000030
.
5.
Palladini
G
,
Milani
P
,
Merlini
G.
Management of AL amyloidosis in 2020
.
Blood
.
2020
;
136
(
23
):
2620
-
2627
.
doi:10.1182/blood.2020006913
.
6.
Jimenez-Zepeda
V
,
Bril
V
,
Lemieux-Blanchard
E
, et al.
A comprehensive multidisciplinary diagnostic algorithm for the early and efficient detection of amyloidosis
.
Clin Lymphoma Myeloma Leuk
.
2023
;
23
(
3
):
194
-
202
.
doi:10.1016/j.clml.2022.12.013
.
7.
The great imitator
. Wikipedia. https://en.wikipedia.org/wiki/The_great_imitator. Accessed
May
31
,
2023
.
8.
McCausland
KL
,
White
MK
,
Guthrie
SD
, et al.
Light chain (AL) amyloidosis: the journey to diagnosis
.
Patient
.
2018
;
11
(
2
):
207
-
216
.
doi:10.1007/s40271-017-0273-5
.
9.
Hester
LL
,
Gifkins
DM
,
Bellew
KM
, et al.
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019
.
Eur J Haematol
.
2021
;
107
(
4
):
428
-
435
.
doi:10.1111/ejh.13679
.
10.
D'Souza
A
,
Pezzin
L
,
Laud
P
,
Singh
A.
Racial disparities in patients diagnosed with light chain (AL) amyloidosis
.
Blood Cancer J
.
2021
;
11
(
4
):
72
.
doi:10.1038/s41408-021-00466-8
.
11.
Kourelis
TV
,
Kumar
SK
,
Go
RS
, et al.
Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias
.
Am J Hematol
.
2014
;
89
(
11
):
1051
-
1054
.
doi:10.1002/ajh.23827
.
12.
Palladini
G
,
Basset
M
,
Milani
P
, et al.
Biomarker-based screening of organ dysfunction in patients with MGUS allows early diagnosis of AL amyloidosis
.
Blood
.
2017
;
130
(
suppl 1
):
1760
.
doi:10.1182/blood.V130.Suppl_1.1760.1760
.
13.
Cuddy
SAM
,
Chetrit
M
,
Jankowski
M
, et al.
Practical points for echocardiography in cardiac amyloidosis
.
J Am Soc Echocardiogr
.
2022
;
35
(
9
):
A31
-
A40
.
doi:10.1016/j.echo.2022.06.006
.
14.
Gillmore
JD
,
Maurer
MS
,
Falk
RH
, et al.
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
.
Circulation
.
2016
;
133
(
24
):
2404
-
2412
.
doi:10.1161/CIRCULATIONAHA.116.021612
.
15.
Bokhari
S
,
Castaño
A
,
Pozniakoff
T
,
Deslisle
S
,
Latif
F
,
Maurer
MS
.
(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses
.
Circ Cardiovasc Imaging
.
2013
;
6
(
2
):
195
-
201
.
doi:10.1161/CIRCIMAGING.112.000132
.
16.
Zhao
L
,
Tian
Z
,
Fang
Q.
Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis
.
BMC Cardiovasc Disord
.
2016
;
16
:
129
.
doi:10.1186/s12872-016-0311-6
.
17.
Hawkins
PN
,
Lavender
JP
,
Pepys
MB
.
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component
.
N Engl J Med
.
1990
;
323
(
8
):
508
-
513
.
doi:10.1056/NEJM199008233230803
.
18.
Ehman
EC
,
El-Sady
MS
,
Kijewski
MF
, et al.
Early detection of multiorgan light-chain amyloidosis by whole-body 18F-florbetapir PET/CT
.
J Nucl Med
.
2019
;
60
(
9
):
1234
-
1239
.
doi:10.2967/jnumed.118.221770
.
19.
Wall
J
,
Martin
E
,
Heidel
E
, et al.
Detection of systemic AL amyloidosis by 124I-p5 + 14 PET/CT imaging - providing the complete picture for diagnosis
.
Blood
.
2021
;
138
(
suppl 1
):
2952
.
doi:10.1182/blood-2021-154327
.
20.
Katzmann
JA
.
Screening panels for monoclonal gammopathies: time to change
.
Clin Biochem Rev
.
2009
;
30
(
3
):
105
-
111
. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754998/.
21.
Muchtar
E
,
Dispenzieri
A
,
Lacy
MQ
, et al.
Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition
.
Ann Med
.
2017
;
49
(
7
):
545
-
551
.
doi:10.1080/07853890.2017.1304649
.
22.
Fernandez de Larrea
C
,
Verga
L
,
Morbini
P
, et al.
A practical approach to the diagnosis of systemic amyloidoses
.
Blood
.
2015
;
125
(
14
):
2239
-
2244
.
doi:10.1182/blood-2014-11-609883
.
23.
El-Meanawy
A
,
Mueller
C
,
Iczkowski
KA
.
Improving sensitivity of amyloid detection by Congo red stain by using polarizing microscope and avoiding pitfalls
.
Diagn Pathol
.
2019
;
14
(
1
):
57
.
doi:10.1186/s13000-019-0822-4
.
24.
Bowen
K
,
Shah
N
,
Lewin
M.
AL-amyloidosis presenting with negative Congo red staining in the setting of high clinical suspicion: a case report
.
Case Rep Nephrol
.
2012
;
2012
:593460.
doi:10.1155/2012/593460
.
25.
Schönland
SO
,
Hegenbart
U
,
Bochtler
T
, et al.
Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients
.
Blood
.
2012
;
119
(
2
):
488
-
493
.
doi:10.1182/blood-2011-06-358507
.
26.
Picken
MM
,
Herrera
GA
.
The burden of “sticky” amyloid: typing challenges
.
Arch Pathol Lab Med
.
2007
;
131
(
6
):
850
-
851
.
doi:10.5858/2007-131-850-TBOSAT
.
27.
Dasari
S
,
Theis
JD
,
Vrana
JA
, et al.
Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples
.
Mayo Clin Proc
.
2020
;
95
(
9
):
1852
-
1864
.
doi:10.1016/j.mayocp.2020.06.029
.
28.
Benson
MD
,
Berk
JL
,
Dispenzieri
A
, et al.
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres
.
Amyloid
.
2022
;
29
(
1
):
8
-
13
.
doi:10.1080/13506129.2021.1994386
.
29.
Sidiqi
MH
,
McPhail
ED
,
Theis
JD
, et al.
Two types of amyloidosis presenting in a single patient: a case series
.
Blood Cancer J
.
2019
;
9
(
3
):
30
.
doi:10.1038/s41408-019-0193-9
.
30.
Kourelis
TV
,
Kyle
RA
,
Dingli
D
, et al.
Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience
.
Mayo Clin Proc
.
2017
;
92
(
6
):
908
-
917
.
doi:10.1016/j.mayocp.2017.02.016
.
31.
Mahmoud
S
,
Sachchithanantham
S
,
Bridoux
F
, et al.
Risk of progression of localised amyloidosis to systemic disease in 606 patients over 30 years
.
Blood
.
2013
;
122
:
3143
.
doi:10.1182/blood.V122.21.3143.3143
.
32.
Dispenzieri
A
,
Gertz
MA
,
Kyle
RA
, et al.
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
.
J Clin Oncol
.
2004
;
22
(
18
):
3751
-
3757
.
doi:10.1200/JCO.2004.03.029
.
33.
Wechalekar
AD
,
Schonland
SO
,
Kastritis
E
, et al.
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
.
Blood
.
2013
;
121
(
17
):
3420
-
3427
.
doi:10.1182/blood-2012-12-473066
.
34.
Kumar
S
,
Dispenzieri
A
,
Lacy
MQ
, et al.
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
.
J Clin Oncol
.
2012
;
30
(
9
):
989
-
995
.
doi:10.1200/JCO.2011.38.5724
.
35.
Palladini
G
,
Hegenbart
U
,
Milani
P
, et al.
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
.
Blood
.
2014
;
124
(
15
):
2325
-
2332
.
doi:10.1182/blood-2014-04-570010
.
36.
Grogan
M
,
Scott
CG
,
Kyle
RA
, et al.
Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system
.
J Am Coll Cardiol
.
2016
;
68
(
10
):
1014
-
1020
.
doi:10.1016/j.jacc.2016.06.033
.
37.
Gillmore
JD
,
Damy
T
,
Fontana
M
, et al.
A new staging system for cardiac transthyretin amyloidosis
.
Eur Heart J
.
2018
;
39
(
30
):
2799
-
2806
.
doi:10.1093/eurheartj/ehx589
.
38.
Muchtar
E
,
Kumar
SK
,
Gertz
MA
, et al.
Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay
.
Blood
.
2019
;
133
(
7
):
763
-
766
.
doi:10.1182/blood-2018-10-875252
.
You do not currently have access to this content.